<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00283218</url>
  </required_header>
  <id_info>
    <org_study_id>Asp-BIAsp-2005/0109</org_study_id>
    <nct_id>NCT00283218</nct_id>
  </id_info>
  <brief_title>A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.</brief_title>
  <official_title>A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70. - A Randomised, Quadruple Cross-Over Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <brief_summary>
    <textblock>
      The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin
      analogues will improve post prandial glycaemic control in patients with type 1 diabetes.

      OBJECTIVE:

      The objective is to describe pharmacodynamic (PD) and pharmacokinetic (PK) profiles of
      Insulin Aspart (IAsp), Biphasic Insulin Aspart (BIAsp) 30, 50 and 70 for a period of 12 hours
      following a standard test meal on four days respectively in subjects with type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a single centre, open-label, randomised 4 period cross-over trial, comparing
      the pk and pd profiles of IAsp, BIAsp 30, BIAsp 50 and BIAsp 70 after a standard test meal in
      subjects with type 1 diabetes. The profiles will be derived over a 12-hour period after
      subcutaneous injection in the abdominal region with a single dose of IAsp, BIAsp 30, BIAsp 50
      or BIAsp 70 at a test meal. The trial consists of a screening period of 4-21 days and 4
      treatment visits
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date>August 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint:</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>• Cmaxglu: Peak plasma glucose following test meal (breakfast). A comparison will be made between BIAsp 50 vs BIAsp 70, BIAsp 30 vs BIAsp 70, BIAsp 30 vs BIAsp 50 and IAsp vs BIAsp 30, 50 and 70.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints:</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCglu: The area under the plasma glucose concentration (0-12, 0-6, 6-12, 0-4, 4-8, 8-12 hours after test meal) after a single injection of one of the four insulin aspart preparation: IAsp (NovoRapid®), Biphasic insulin aspart 30, 50 and 70.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCins: The area under insulin aspart concentration (0-12, 0-6, 6-12, 0-4, 4-8, 8-12 hours after test meal) after a single injection of one of the four insulin aspart preparation: IAsp (NovoRapid®), Biphasic insulin aspart 30, 50 and 70.</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent obtained before any trial-related activities.

          2. Diagnosed type 1 diabetes before the age of 40 and on insulin treatment within one
             year of diagnosis.

          3. Insulin treatment of any regime for more than one year at time of inclusion.

          4. Total insulin demand ≥ 0,5 IU/kg/24 hrs

          5. HbA1c between 7% and 12 % (both values included).

          6. Age ≥ 18 years.

          7. BMI between 18 and 35 kg /m2 (including both values).

        Exclusion Criteria:

          1. Known or suspected allergy to trial product(s) or related products.

          2. Recurrent major hypoglycaemic episodes.

          3. Heart: Unstable Angina Pectoris, AMI &lt; 12 months or heart insufficiency classified
             according to NYHA III-IV

          4. Blood Pressure: Severe uncontrolled hypertension with BP &gt; 180/110 mmHg, sitting

          5. Liver: Impaired hepatic function corresponding to serum-ALAT or –basic phosphatase &gt;
             2x upper reference limit of the local laboratory.

          6. Kidneys: Impaired renal function corresponding to serum-creatinin &gt; 150 μmol/l
             according to the local laboratory.

          7. Any disease judged by the investigator to affect the trial.

          8. Pregnancy, breast feeding or the intention of becoming pregnant or fertile women not
             using adequate contraceptive measures – adequate contraceptive method is
             sterilisation, hysterectomy or current use of contraceptive pills or intra uterine
             device.

          9. The receipt of any investigational drug within a three month period prior to this
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens S Christiansen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicinsk Afd. M, Århus Sygehus, Nørrebrogade 44, 8000 Århus C</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tina Parkner, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Medicinsk Afd. M, Århus Sygehus, Nørrebrogade 44, 8000 Århus C</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niels Ejskjaer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Medicinsk afd. M, Århus Sygehus, Nørrebrogade 44, 8000 Århus C</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rannveig L Thorisdottir, Stud.med</last_name>
    <role>Study Director</role>
    <affiliation>Medicinsk afd. M, Århus Sygehus, Nørrebrogade 44, 8000 Århus C</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept of Medicine M, Aarhus University Hospital, Nørrebrogade 44</name>
      <address>
        <city>Aarhus</city>
        <state>C</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care. 1997 Oct;20(10):1612-4.</citation>
    <PMID>9314644</PMID>
  </reference>
  <reference>
    <citation>Jacobsen LV, Søgaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol. 2000 Aug;56(5):399-403.</citation>
    <PMID>11009049</PMID>
  </reference>
  <reference>
    <citation>Kang S, Creagh FM, Peters JR, Brange J, Vølund A, Owens DR. Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care. 1991 Jul;14(7):571-7.</citation>
    <PMID>1914797</PMID>
  </reference>
  <reference>
    <citation>Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med. 2002 May;19(5):393-9. Erratum in: Diabet Med. 2002 Sep;19(9):797..</citation>
    <PMID>12027927</PMID>
  </reference>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2006</study_first_submitted>
  <study_first_submitted_qc>January 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <last_update_submitted>August 7, 2006</last_update_submitted>
  <last_update_submitted_qc>August 7, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

